{"datasetJSONCreationDateTime":"2024-12-18T15:34:17","datasetJSONVersion":"1.1.0","fileOID":"CDISCPILOT01.ts","dbLastModifiedDateTime":"2024-12-18T15:30:46","originator":"CDISC Data Exchange Standards Team","sourceSystem":{"name":"SAS on X64_10PRO","version":"9.0401M7"},"studyOID":"CDISCPILOT01","metaDataVersionOID":"CDISC.SDTMIG.3.1.2","metaDataRef":"define.xml","itemGroupOID":"TS","records":33,"name":"TS","label":"Trial Summary","columns":[{"itemOID":"TS.STUDYID","name":"STUDYID","label":"Study Identifier","dataType":"string","length":12,"keySequence":1},{"itemOID":"TS.DOMAIN","name":"DOMAIN","label":"Domain Abbreviation","dataType":"string","length":2},{"itemOID":"TS.TSSEQ","name":"TSSEQ","label":"Sequence Number","dataType":"integer","keySequence":3},{"itemOID":"TS.TSPARMCD","name":"TSPARMCD","label":"Trial Summary Parameter Short Name","dataType":"string","length":200,"keySequence":2},{"itemOID":"TS.TSPARM","name":"TSPARM","label":"Trial Summary Parameter","dataType":"string","length":200},{"itemOID":"TS.TSVAL","name":"TSVAL","label":"Parameter Value","dataType":"string","length":200}],"rows":[["CDISCPILOT01","TS",1,"ADDON","Added on to Existing Treatments","Y"],["CDISCPILOT01","TS",1,"AGEMAX","Planned Maximum Age of Subjects","No maximum"],["CDISCPILOT01","TS",1,"AGEMIN","Planned Minimum Age of Subjects","50 years"],["CDISCPILOT01","TS",1,"AGESPAN","Age Group","ADULT (18-65)"],["CDISCPILOT01","TS",2,"AGESPAN","Age Group","ELDERLY (> 65)"],["CDISCPILOT01","TS",1,"TBLIND","Trial Blinding Schema","DOUBLE BLIND"],["CDISCPILOT01","TS",1,"COMPTRT","Comparative Treatment Name","Placebo"],["CDISCPILOT01","TS",1,"TCNTRL","Control Type","PLACEBO"],["CDISCPILOT01","TS",1,"TDIGRP","Diagnosis Group","Patients with Probable Mild to Moderate Alzheimer's Disease"],["CDISCPILOT01","TS",1,"DOSE","Dose per Administration","54"],["CDISCPILOT01","TS",2,"DOSE","Dose per Administration","81"],["CDISCPILOT01","TS",1,"DOSFRQ","Dosing Frequency","QD; 12 to 14 hours transdermal application"],["CDISCPILOT01","TS",1,"DOSU","Dose Units","mg"],["CDISCPILOT01","TS",1,"INDIC","Trial Indication","Mild to Moderate Alzheimer's Disease"],["CDISCPILOT01","TS",1,"TINDTP","Trial Indication Type","TREATMENT"],["CDISCPILOT01","TS",1,"LENGTH","Trial Length","26 weeks"],["CDISCPILOT01","TS",1,"OBJPRIM","Trial Primary Objective","To determine if there is a statistically significant relationship between the change in both ADAS-Cog and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg])"],["CDISCPILOT01","TS",2,"OBJPRIM","Trial Primary Objective","To document the safety profile of the xanomeline TTS."],["CDISCPILOT01","TS",1,"OBJSEC","Trial Secondary Objective","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas."],["CDISCPILOT01","TS",2,"OBJSEC","Trial Secondary Objective","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas."],["CDISCPILOT01","TS",3,"OBJSEC","Trial Secondary Objective","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The ADAS-Cog (14) will be used for this assessment."],["CDISCPILOT01","TS",4,"OBJSEC","Trial Secondary Objective","To assess the treatment response as a function of Apo E genotype."],["CDISCPILOT01","TS",1,"TPHASE","Trial Phase Classification","Phase II Trial"],["CDISCPILOT01","TS",1,"PLANSUB","Planned Number of Subjects","300"],["CDISCPILOT01","TS",1,"RANDOM","Trial is Randomized","Y"],["CDISCPILOT01","TS",1,"ROUTE","Route of Administration","TRANSDERMAL"],["CDISCPILOT01","TS",1,"SEXPOP","Sex of Participants","BOTH"],["CDISCPILOT01","TS",1,"SPONSOR","Clinical Study Sponsor","CDISCPILOT01"],["CDISCPILOT01","TS",1,"TITLE","Trial Title","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease."],["CDISCPILOT01","TS",1,"TRT","Investigational Therapy or Treatment","Xanomeline"],["CDISCPILOT01","TS",1,"TTYPE","Trial Type","SAFETY"],["CDISCPILOT01","TS",2,"TTYPE","Trial Type","EFFICACY"],["CDISCPILOT01","TS",4,"TTYPE","Trial Type","PHARMACOKINETIC"]]}